Phi-Medics

Phi-Medics is a private, London-based consultancy founded in 2016, specializing in providing strategic and operational services to pharmaceutical companies, primarily in oncology and hematology. The company's business model is entirely service-based, offering expertise in clinical R&D, medical affairs, and disease strategy on a project or interim management basis. Led by founder Christine Wilkinson Blanc, it is a boutique firm likely operating with a small team, generating revenue through client fees. Its value proposition centers on the founder's extensive, hands-on experience in bringing complex therapeutics from development to market.

The company does not own a proprietary technology platform. Its core asset is the founder's extensive expertise and strategic methodology in end-to-end pharmaceutical development, specifically for oncology/hematology products across modalities like small molecules, antibodies, vaccines, and radiopharmaceuticals.

Phi-Medics competes in the crowded pharmaceutical consulting sector, facing competition from large global CROs, broad-spectrum management consultancies, and numerous independent specialists. Its differentiator is the deep, hands-on oncology/hematology development experience of its founder, offering a personalized, high-touch alternative to larger firms.